Olmesartan Medoxomil (OM) on left ventricle hypertrophy (LVH) and inflammatory cytokines
IL-6 and IL-10 levels in renovascular hypertensive rats. MATERIALS AND METHODS …

Olmesartan, as a new angiotensin II receptor blocker, has shown beneficial effects on
cardiovascular diseases. Nevertheless, the effect of olmesartan on ischemia/reperfusion …

Our group has previously demonstrated that short‐term treatment with esmolol reduces left
ventricular hypertrophy (LVH) in spontaneously hypertensive rats (SHRs). The present study …

Left ventricular (LV) fibrosis is one of the most prominent pathophysiological results of
hypertension. We initiated this study to investigate the effects and mechanisms of emodin …

Objective: Interactions between the renin-angiotensin system (RAS) and transforming
growth factor-beta 1 (TGF-β1) have been well documented. The aim was to explore the …

Cardiovascular remodeling contributes to the progression of cardiovascular disease. Thus,
our aim was to evaluate the action of long-term treatment with olmesartan on cardiac and …

Objective: This study was undertaken to determine the biochemical and left ventricular
functional changes associated with reversal of left ventricular hypertrophy (LVH) in …

AIM: To evaluate the antihypertensive efficacy of angiotensin converting enzyme inhibitor
(ACEI) benazepril in combination with AT1 receptor antagonist valsartan and their effect on …

Favorable effects of angiotensin II type 1 receptor blockers on patients with ischemic or
idiopathic dilated cardiomyopathy (DCM) have already been suggested by several human …

Objective To investigate effects of lorsartan, fosinopril on myocardial fibrosis, angiotensin II
and cardiac remolding in the spontaneously hypertensive rats (SHR). Methods 16-week-old …